These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 3263234

  • 1. Differential immunosuppressive action of carbimazole and propylthiouracil.
    Wilson R, McKillop JH, Pearson C, Burnett AK, Thomson JA.
    Clin Exp Immunol; 1988 Aug; 73(2):312-5. PubMed ID: 3263234
    [Abstract] [Full Text] [Related]

  • 2. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW.
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [Abstract] [Full Text] [Related]

  • 3. Increased activated T-lymphocytes and normal thyrotropin receptor antibody levels in Graves' disease in long-term remission.
    Peakman M, Hussain M, Cundy T, Vergani D.
    J Clin Lab Immunol; 1989 Sep; 30(1):1-5. PubMed ID: 2577115
    [Abstract] [Full Text] [Related]

  • 4. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
    Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, Savage CO, Franklyn JA.
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):671-5. PubMed ID: 15163328
    [Abstract] [Full Text] [Related]

  • 5. Absence of gradient of thyrotropin receptor antibody and T cell subset distribution between thyroid and peripheral venous blood in patients with Graves' disease prepared for surgery with carbimazole and potassium iodide.
    Wilson R, McKillop JH, Pearson C, Burnett AK, Gunn I, McNicol AM, Thomson JA.
    Clin Exp Immunol; 1988 Aug; 73(2):265-8. PubMed ID: 3263232
    [Abstract] [Full Text] [Related]

  • 6. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC, Pei D, Wang TF, Wu DA, Li JC, Wei CL, Lee CH, Chen SP, Kuo SW.
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [Abstract] [Full Text] [Related]

  • 7. Carbimazole and the autoimmune response in Graves' disease.
    McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R.
    N Engl J Med; 1980 Aug 07; 303(6):302-7. PubMed ID: 6247656
    [Abstract] [Full Text] [Related]

  • 8. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T, Holle LH, Schroth HJ, Garth H.
    Nuklearmedizin; 1998 May 07; 37(3):90-4. PubMed ID: 9604228
    [Abstract] [Full Text] [Related]

  • 9. Humoral and cellular immunological factors as possible markers of clinical relapse in HLA-typed Graves' patients followed with time.
    Di Mario U, Vitillo M, Perfetti R, Mancuso M, Morellini M, Cappellacci S, Pozzilli P, Andreani D.
    Horm Metab Res; 1989 May 07; 21(5):267-71. PubMed ID: 2789166
    [Abstract] [Full Text] [Related]

  • 10. Triiodothyronine antibodies in a case of Graves' disease: long-term follow-up under carbimazole.
    Heshmati HM, Izembart M, Turpin G, Vallée G.
    Horm Metab Res; 1991 Mar 07; 23(3):148. PubMed ID: 1864563
    [No Abstract] [Full Text] [Related]

  • 11. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
    Tun NN, Beckett G, Zammitt NN, Strachan MW, Seckl JR, Gibb FW.
    Thyroid; 2016 Aug 07; 26(8):1004-9. PubMed ID: 27266892
    [Abstract] [Full Text] [Related]

  • 12. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seissler J.
    Horm Metab Res; 2004 Feb 07; 36(2):92-6. PubMed ID: 15002058
    [Abstract] [Full Text] [Related]

  • 13. Studies of autoimmunity in Graves' disease before and after treatment with carbimazole.
    Zosin I, Arcan P, Lungu G, Cotoi A, Opreanu R.
    Endocrinologie; 1988 Feb 07; 26(1):49-53. PubMed ID: 3260398
    [Abstract] [Full Text] [Related]

  • 14. Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease.
    Charreire J, Karsenty G, Bouchard P, Schaison G.
    Clin Exp Immunol; 1984 Sep 07; 57(3):633-8. PubMed ID: 6147216
    [Abstract] [Full Text] [Related]

  • 15. [Hyperthyroidism in a premature infant due to transplacental passage of maternal thyrotropin receptor antibodies].
    Rink T, Wieg C, Schroth HJ, Helisch A, Bertram U.
    Nuklearmedizin; 1999 Sep 07; 38(5):156-9. PubMed ID: 10488483
    [Abstract] [Full Text] [Related]

  • 16. [Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995].
    Escobar Jiménez F, Luna López V, Fernández Soto ML, Quezada Charneco M, Glinoer D.
    Med Clin (Barc); 1998 Sep 05; 111(6):205-10. PubMed ID: 9789225
    [Abstract] [Full Text] [Related]

  • 17. Treatment outcome of Graves' disease in Thai children.
    Somnuke PH, Pusuwan P, Likitmaskul S, Santiprabhob J, Sawathiparnich P.
    J Med Assoc Thai; 2007 Sep 05; 90(9):1815-20. PubMed ID: 17957924
    [Abstract] [Full Text] [Related]

  • 18. The use of the E-rosette as a test for remission in Graves' disease treated with antithyroid drugs.
    Farid NR, Munro R, Row VV, Volpé R.
    Clin Endocrinol (Oxf); 1974 Jan 05; 3(1):55-61. PubMed ID: 4407296
    [No Abstract] [Full Text] [Related]

  • 19. [The association of Graves' disease with serum soluble interleukin 2 receptor].
    Ren YZ, Song ZG.
    Zhonghua Yi Xue Za Zhi; 1993 May 05; 73(5):264-5, 317. PubMed ID: 8221241
    [Abstract] [Full Text] [Related]

  • 20. Class IV lupus nephritis associated with Graves' disease.
    Fu LS, Yang LY, Chen WP, Chao T, Ooi SK, Lin CY.
    Child Nephrol Urol; 1992 May 05; 12(1):51-4. PubMed ID: 1606584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.